NASDAQ:CAPS

Capstone Therapeutics Q1 2026 Earnings Report

Capstone Therapeutics logo
$0.29 0.00 (-1.36%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$0.29 +0.00 (+0.69%)
As of 06/18/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Capstone Therapeutics EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Capstone Therapeutics Revenue Results

Actual Revenue
$12.64 million
Expected Revenue
$10.80 million
Beat/Miss
Beat by +$1.84 million
YoY Revenue Growth
N/A

Capstone Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 20, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Capstone Therapeutics' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Capstone Therapeutics Earnings Headlines

Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight.tc pixel
Capstone Holding Stock Price History
See More Capstone Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email.

About Capstone Therapeutics

Capstone Therapeutics (NASDAQ:CAPS), a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

View Capstone Therapeutics Profile